Introduction: Uremic xerosis with pruritus (UXP) is a chronic cutaneous complication among patients undergoing maintenance renal dialysis. Uremic xerosis level is directly related with pruritus severity or vice versa. Uremic xerosis with pruritus may lead to discomfort and negative psychological effect. The ethiopathogenesis still unknown, Most of treatments are empirical, and there is no effective and safe therapy. Emollient has not been effective enough to improve quality of life. There is some report about efficacy of topical vitamin D in xerosis and chronic pruritus. Objective: We evaluate the efficacy of calcipotriol 0.005% ointment for uremic xerosis and uremic pruritus in chronic kidney disease patients undergoing hemodialysis. Material & methode: Sixty two patients with UXP were enrolled, randomized double blind study. Patients were divided to two group, calcipotriol 0.005% ointment group or placebo. In baseline, patients were instructed to apply twice daily for four weeks. We assesesment the efficacy and safety of calcipotriol 0.005% ointment and placebo after 2nd and 4th weeks treatment using overall dry skin score (ODSS), visual analog scale (VAS), corneometer and sebumeter. We also assessed adverse effect and tolerance this drugs using visual assessment scale. Results: Overall dry skin score (ODSS) and visual analog scale (VAS) significantly decreased in calcipotriol 0.005% ointment group than in placebo group (p <0.05). Skin hydration level based on Corneometer score and skin surface lipid based on Sebumeter score was significantly increased in calcipotriol 0.005% ointment group than in placebo group (p <0.05). Cure rate and clinical improvement for calcipotriol 0.005% ointment group was significantly higher than placebo group. There was no adverse effect between two groups after treatment. Conclusion: calcipotriol 0.005% ointment is effective than placebo and can be used as alternative or adjuctive treatment and safe and tolerance for UXP.

A B S T R A C TRenal pruritus (RP) is a condition or symptom that is often found in end-stagechronic kidney disease (CKD) undergoing hemodialysis (HD). The etiology of RP ismultifactorial, one of it due to inflammation mediated by interleukin 2 (IL-2). Studyon the correlation between serum level of IL-2 and the severity of RP is still limited.This study will analyze the correlation between serum level of IL-2 in patientsundergoing HD and the severity of RP. Our method is cross sectional design atHemodialysis Installation of Dr. Mohammad Hoesin Hospital. Serum level of IL-2examined by ELISA, the severity of RP assessed by a 5 dimensional pruritus scale.Inclusion criteria in this study included HD patients with RP ≥ 9, age ≥ 18 years andwilling to sign informed consent. The results from 28 male (59.6%) and 19 female(40.4%) are the mean serum level of IL-2 (pg/ml) is 0.424 ± 0.077. The mean RPseverity score is 18.98 ± 2.74. A strong positive correlation between serum level ofIL-2 and the severity of RP (r = 0.750, p = 0,000). Our conclusion is the increase ofserum level IL-2 in line with severity of RP.

Abstract Background: Leprosy is a chronic infectious disease caused by Mycobacterium leprae (M. leprae). Distribution of leprosy cases in the world in 2015 was highest in the Southeast Asia region, with 156,118 cases. The increase in new cases and the high prevalence of leprosy requires action to break the chain of transmission. Household contact groups are easy to identify by the research group, because the group has good reasons for examining or getting chemoprophylaxis. Objectives: Our objective was to compare Phenolic Glycolipid 1 (PGL-1) antibody levels in household contacts of pausibasilary (PB) and multibacilary (MB) patients. Methods: This study was a analytic observational study with a cross-sectional design. ELISA examination will be conducted at the Leprosy Laboratory of the Institute of Tropical Diseases, Airlangga University, Surabaya. The study was conducted from 3 December 2019 to 31 January 2020, with a total sample of 60 samples. Resuls: PGL-1 antibodies in MB leprosy household contact were greater than PGL-1 antibodies in PB leprosy household contact, and the results showed statistically significant (p = 0.011). Conclusions: There are differences in the levels of PGL-1 antibodies between household contact PB leprosy patients and MB. The household contact PGL-1 antibody levels in MB leprosy are greater than PB leprosy.

Introduction: Uremic xerosis with pruritus (UXP) is a chronic cutaneous complication among patients undergoing maintenance renal dialysis. Uremic xerosis level is directly related with pruritus severity or vice versa. Uremic xerosis with pruritus may lead to discomfort and negative psychological effect. The ethiopathogenesis still unknown, Most of treatments are empirical, and there is no effective and safe therapy. Emollient has not been effective enough to improve quality of life. There is some report about efficacy of topical vitamin D in xerosis and chronic pruritus. Objective: We evaluate the efficacy of calcipotriol 0.005% ointment for uremic xerosis and uremic pruritus in chronic kidney disease patients undergoing hemodialysis. Material & methode: Sixty two patients with UXP were enrolled, randomized double blind study. Patients were divided to two group, calcipotriol 0.005% ointment group or placebo. In baseline, patients were instructed to apply twice daily for four weeks. We assesesment the efficacy and safety of calcipotriol 0.005% ointment and placebo after 2nd and 4th weeks treatment using overall dry skin score (ODSS), visual analog scale (VAS), corneometer and sebumeter. We also assessed adverse effect and tolerance this drugs using visual assessment scale. Results: Overall dry skin score (ODSS) and visual analog scale (VAS) significantly decreased in calcipotriol 0.005% ointment group than in placebo group (p <0.05). Skin hydration level based on Corneometer score and skin surface lipid based on Sebumeter score was significantly increased in calcipotriol 0.005% ointment group than in placebo group (p <0.05). Cure rate and clinical improvement for calcipotriol 0.005% ointment group was significantly higher than placebo group. There was no adverse effect between two groups after treatment. Conclusion: calcipotriol 0.005% ointment is effective than placebo and can be used as alternative or adjuctive treatment and safe and tolerance for UXP.

Diabetes mellitus (DM) is a chronic and complex disease that affects various parts of the body. It can lead to multiple systemic complications and also cutaneous manifestation. Diabetic foot ulcer (DFU) is one of the most devastating complications of DM in dermatology. The main etiology is an increase in plasma glucose, risk factors, or comorbidities due to DM itself. Neglected DFU can lead to further complications, including high amputation and mortality rates; thus, the healing of ulcers is the main objective of the treatment. Management is divided into the standard of care and adjuvant therapies. This study aims to optimize DFU management, so it can provide proper treatment and prevent complications.